Biogen (NASDAQ: BIIB)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Biogen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biogen Company Info
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
News & Analysis
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.
One is slightly cheaper than the other.
The company's fascinating saga in the Alzheimer's disease drug market continues.
Biogen stock has dropped about 40% from its record high.
It could be a make or break year for the biotech.
Its new drug might succeed where the company faltered in 2021.
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Valuation
Podcast Episodes
We examine three biotech companies' past performances and future outlooks.
The biotech popped 30% after the extremely unusual revival of an Alzheimer's treatment that had looked like a failure at first.
Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.
The Industry Focus team compares Biogen's and Celgene's current valuations and considers what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
Earnings Transcripts
BIIB earnings call for the period ending December 31, 2022.
BIIB earnings call for the period ending September 30, 2022.
BIIB earnings call for the period ending June 30, 2022.
BIIB earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.